Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

作者： Rene Machietto1, Nicholas Giacobbe1, Jessica Perazzelli2, Ted J. Hofmann2, Allison Barz Leahy2,3, Stephan A. Grupp1,2,3, Yongping Wang1,3,4, Stephan Kadauke1,3,4 1Cell and Gene Therapy Laboratory, Department of Pathology and Laboratory Medicine,Children’s Hospital of Philadelphia, 2Division of Oncology, Department of Pediatrics,Children’s Hospital of Philadelphia, 3Perelman School of Medicine at the University of Pennsylvania, 4Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine,Children’s Hospital of Philadelphia

简介：

Overview

This article details a semi-automated process for manufacturing chimeric antigen receptor T cells (CAR T-cells) for clinical use. The method utilizes an automated cell processor for viral transduction and cultivation, offering flexibility and cost-effectiveness compared to commercial alternatives.

Key Study Components

Area of Science

• Cell and gene therapy
• Immunotherapy
• Clinical trial methodology

Background

• Chimeric antigen receptor T cells are a promising treatment for various cancers.
• Manufacturing CAR T-cells traditionally involves complex, labor-intensive processes.
• Automation can enhance efficiency and reduce costs in cell production.
• Closed systems are essential for maintaining sterility and safety in clinical applications.

Purpose of Study

• To present a protocol for the semi-automated production of CAR T-cells.
• To identify potential pitfalls in the process development for clinical trials.
• To explore the adaptability of the method for other cell and gene therapies.

Methods Used

• Utilization of an automated cell processor for T-cell cultivation.
• Viral transduction to introduce CAR genes into T-cells.
• Customization of protocols through computer control.
• Implementation in a closed system to ensure sterility.

Main Results

• The protocol allows for the production of clinical-grade CAR T-cells at lower costs.
• Flexibility in protocol customization enhances usability in various settings.
• The method can be adapted for CAR T-cells targeting different antigens.
• Potential for broader applications in other cell and gene therapies.

Conclusions

• The semi-automated process is a viable alternative to traditional CAR T-cell manufacturing.
• Cost-effectiveness and adaptability are significant advantages of this method.
• Further exploration of additional CAR T-cell targets and gene therapies is warranted.

Frequently Asked Questions